(Q34310415)

1 August 2017

title

Component pathogen inactivation: a critical review (English)

1 reference

1 August 2017

C V Prowse

1

1 reference

1 August 2017

publication date

8 November 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

104

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

183-199

1 reference

Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Spore-forming organisms in platelet concentrates: a challenge in transfusion bacterial safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Establishment of the first international repository for transfusion-relevant bacteria reference strains: ISBT working party transfusion-transmitted infectious diseases (WP-TTID), subgroup on bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

The role of toxicology assessment in transfusion medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Preclinical safety profile of plasma prepared using the INTERCEPT Blood System

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Emerging infectious disease agents and their potential threat to transfusion safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Defining "adequate" pathogen reduction performance for transfused blood components

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

White blood cell inactivation after treatment with riboflavin and ultraviolet light

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Properties of pathogen-inactivated plasma components

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Clinical studies with solvent detergent-treated products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Epidemiology of Transfusion Related Acute Lung Injury in France: Preliminary Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

ADAMTS-13 activity and von Willebrand factor levels in methylene-blue photo-inactivated plasma processed by either the Springe method or an 'in house' system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Anaphylactic reaction after methylene blue-treated plasma transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Anaphylactic shock to fresh‐frozen plasma inactivated with methylene blue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Dose of prophylactic platelet transfusions and prevention of hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

The extent of amotosalen photodegradation during photochemical treatment of platelet components correlates with the level of pathogen inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Economics of pathogen inactivation technology for platelet concentrates in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Viability of red cells prepared with S-303 pathogen inactivation treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2012.01662.X

10.1111/J.1423-0410.2012.01662.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference